
Needle-spiking attacks in France prompt government warning, public fear
The attacks, carried out by unknown assailants who prick their victims with needles, have raised concerns that the instruments could be contaminated with diseases or harmful substances. Authorities have announced 12 arrests in connection with such incidents, as anxiety grows ahead of large public gatherings for Bastille Day and summer music festivals.
The phenomenon first emerged in 2022 but has seen a recent surge. During the nationwide Fête de la Musique on June 21, 145 people reported being pricked, following calls on social media for mass spiking attacks, particularly against women. Incidents have also been reported at the Printemps de Bourges festival and in nightclubs and on public transport in cities including Paris, Nantes, and Grenoble.
In response, Justice Minister Gérald Darmanin has sent a circular to all public prosecutors demanding a 'swift' and decisive response to the incidents and ordering that specific investigation procedures be implemented immediately to preserve evidence.
'One person told me, 'I was pricked at the Fête de la Musique',' one victim said in a weary, clipped tone. 'At one point, someone passed by me, and I felt a sharp sting.'
Judicial authorities have opened multiple investigations into the attacks, which have left victims with a range of symptoms. According to a 2024 study of several hundred of the 1,200 people who filed complaints that year, some victims initially felt a prick in the arm or thigh, later noticing marks. Others subsequently developed symptoms such as dizziness, hot flashes, or severe headaches.
Professor Joseph Bakhache, an infectious diseases specialist, said it remains difficult to confirm if injections of harmful substances have actually occurred, as clinical and laboratory tests have so far failed to provide proof.
'The most difficult task for us is to follow up on the type of needle used, especially as there are needles that can transmit infectious and chronic diseases, such as AIDS and Hepatitis B,' Bakhache told Asharq News. 'The real fear for us remains on the trains, which are used by millions of citizens daily across France.'
He noted that, unlike narcotics, some injectable substances are difficult to detect, and expressed serious concern over the potential use of contaminated, second-hand needles.
Darmanin's circular stressed the need for comprehensive victim support and outlined the legal approach. If tests show a substance was injected, the crime will be treated as the administration of a harmful substance. If a prick is proven but no substance is found, it can be considered intentional violence with a weapon.
Local officials and event organisers have described the phenomenon as a 'real source of concern.' Michel Grouyer, the mayor of Chatou, which is preparing to host the major 'Electric Park' music festival in August, said prevention is difficult given that small needles or pins can be used.
'We have started to prepare and train police officers for non-routine search procedures to prevent, as much as possible, incidents of this type,' he said.
Organisers of some festivals have begun implementing technology to address the issue, such as the 'Safer' mobile app, which allows attendees to immediately report an attack or send an alert. A dedicated team then finds the potential victim to offer assistance, including access to an on-site psychologist.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Mid East Info
3 days ago
- Mid East Info
Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth - Middle East Business News and Information
Dubai, United Arab Emirates;July 2025 — Millions of people are affected by chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands. While chemotherapy and radiation treatment for head and neck cancer are the most common causes of this, aging, certain medications and other factors, including diabetes, stroke, Alzheimer's disease and HIV/AIDS, can also cause chronic dry mouth. Currently, there is no cure for it. Mayo Clinic researchers have established the world's first biobank of human salivary gland tissue-organoids that opens the door to research to find a cure. 'This unique biobank resource overcomes a major barrier we've faced in the field, namely: limited access to standardized salivary specimens suited for salivary gland regeneration research. This collection provides a foundation for regenerative therapy development, especially for radiation-induced chronic dry mouth,' says Nagarajan Kannan, Ph.D., lead author of the study published in NPJ Regenerative Medicine. Dr. Kannan is also the director of the Mayo Clinic Stem Cell and Cancer Biology Laboratory. Nearly 70% of patients with head and neck cancer who are undergoing radiation therapy experience permanent damage to their salivary glands. People with this condition experience diminished quality of life from a constant feeling like cotton is lining their mouths. Besides being uncomfortable, chronic dry mouth can lead to difficulties with chewing, tasting, speaking and swallowing. It also can cause tooth decay. 'Chronic dry mouth can extend long after radiation treatments are complete. It's among the top concerns I hear from patients with head and neck cancer. Unfortunately, there aren't many therapeutics available commercially for these patients,' says co-author Jeffrey Janus, M.D., an ear, nose and throat specialist at Mayo Clinic in Florida. One promising avenue of research is the cultivation of rare regenerative cells to greater numbers that can help people someday heal and grow new, healthy salivary gland cells. The biobank consists of specimens collected from 208 donors. From this repository, researchers have already found biomarkers for mature, saliva-producing cells, and with the help of a high-resolution protein map, they have identified the potential tissue origin of rare, self-renewing salivary cells. The research team also developed a radiation injury model, which paired with the biobank, provides an integrated platform to discover new, personalized regenerative biotherapeutics. This is a collaboration between Mayo Clinic Center for Regenerative Biotherapeutics, Department of Laboratory Medicine and Pathology and Department of Otolaryngology.


See - Sada Elbalad
4 days ago
- See - Sada Elbalad
WHO Recognizes Egypt as Global Leader in Hepatitis C Elimination
H-Tayea Egypt has become the first country in the world to achieve the gold level certification from the World Health Organization (WHO) in its path toward the elimination of Hepatitis C, marking a historic global health milestone. This recognition, officially granted in 2023, highlights Egypt's unparalleled national efforts to tackle a disease that has long been a major public health burden. The achievement was made possible through the ambitious 100 Million Health presidential initiative, one of the largest public health campaigns of its kind, which resulted in over 60 million people being screened for Hepatitis C across the country. More than 4.3 million patients received free treatment, helping reduce liver disease and prevent future complications, including liver cancer. According to WHO, Egypt now accounts for 70 percent of all Hepatitis C treatments in the Eastern Mediterranean Region and 35 percent of all treatments delivered worldwide. Since 2018, Egypt has managed to reduce hepatitis-related deaths by 35 percent, proving that with strong political will and strategic healthcare policies, eliminating a major disease is achievable. On World Hepatitis Day, observed annually on July 28, WHO emphasized that Hepatitis remains a serious health challenge in many parts of the world, particularly in the Eastern Mediterranean Region where 27 million people are infected and nearly 97,000 people die each year from preventable hepatitis-related complications. This year's global theme, 'Simple Steps to Eliminate Hepatitis,' encourages urgent action to expand access to prevention, testing, and treatment. It also calls for removing the social, financial, and systemic barriers—including stigma—that prevent people from receiving care. In another major breakthrough, Egypt in December 2024 became the first country in the Eastern Mediterranean Region to achieve control status for Hepatitis B, having reduced the virus's prevalence to below 5 percent among children aged 9 and older, while maintaining vaccination rates above 90 percent. read more Gold prices rise, 21 Karat at EGP 3685 NATO's Role in Israeli-Palestinian Conflict US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria Shoukry Meets Director-General of FAO Lavrov: confrontation bet. nuclear powers must be avoided News Iran Summons French Ambassador over Foreign Minister Remarks News Aboul Gheit Condemns Israeli Escalation in West Bank News Greek PM: Athens Plays Key Role in Improving Energy Security in Region News One Person Injured in Explosion at Ukrainian Embassy in Madrid News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Sports Get to Know 2025 WWE Evolution Results News "Tensions Escalate: Iran Probes Allegations of Indian Tech Collaboration with Israeli Intelligence" Arts & Culture Hawass Foundation Launches 1st Course to Teach Ancient Egyptian Language


Al-Ahram Weekly
5 days ago
- Al-Ahram Weekly
EU regulator green lights an injectable HIV drug that could help stop transmission - Health - Life & Style
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein. Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men. Winnie Byanyima, executive director of the U.N. AIDS agency, has said the drug 'could change the trajectory of the HIV epidemic' if it is made available to everyone who needs it. In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus. Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills. Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean. But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease. Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS. UNAIDS chief Byanyima has previously suggested that President Donald Trump make a deal with Gilead to produce and license its 'magical' prevention drug lenacapavir across the world to the millions of people who need it. Follow us on: Facebook Instagram Whatsapp Short link: